Navigation Links
Global Intelligence Alliance Strengthens Group Organization and Adds Local Presence, Merges With Asian, German and Dutch Partner Companies
Date:10/14/2008

GIA Group, a global leader in customized Market Intelligence and Strategic Analysis responds to customer needs by merging with partner firms in China, Hong Kong, Singapore, Germany and Netherlands, giving the group 10 offices across three continents and greater access to expertise in strategic analysis and industry verticals.

Helsinki (PRWEB) October 14, 2008 -- Global Intelligence Alliance (GIA, www.globalintelligence.com), a global leader in customized Market Intelligence and Strategic Analysis services and solutions, is proud to announce mergers between GIA Group and three partner companies in the GIA Network: Fusion Consulting, based in Singapore, Hong Kong and Shanghai, Gayer Consulting in Germany, and DeskResearch Nederland in the Netherlands.

The merger is driven by GIA's clients' needs for:
1.   Access to efficient research and in-depth intelligence across the globe
2.   Specialists with local market and industry expertise who understand their clients' businesses
3.   A single partner to provide the full range of customized Market Intelligence and related consulting services

GIA has witnessed growth in demand for Market Intelligence in new geographic areas over the past three years due to the increasing globalization of supply chains, economic slowdown in Europe and North America, and rapid business expansion in the emerging markets. Global Intelligence Alliance specializes in customized Market Intelligence and Strategic Analysis services, and counts among its clients DHL, Fujitsu Services, Henkel, KONE, and Principal Financial Group.

The company is positioned as a single source for international organizations, providing:
1.   Business research and strategic analysis
2.   Co
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

2

GOOD

Page: 1 2

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
4. Briefing on a new Web resource to address global drinking water crisis
5. MDS Pharma Services Wins Award for Management of Global Malaria Trial
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Resonant Medical Appoints New Vice President of Global Sales
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. The era of global aging: GSAs annual meeting to present new research on hot topics in aging
10. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
11. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 1Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 2Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 3Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 4Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 1Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 2Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 3Osseon Receives CE Mark 57784 1Osseon Receives CE Mark 57784 2